{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-012186","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.573295+00:00","generated_at":"2026-06-06T06:41:36.738255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024","bullets":["Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.","Cash and marketable securities $337.2M; expected to fund operations through fiscal 2027.","Anticipates topline data from RSVPEDs Phase 2 study of zelicapavir and EDP-323 Phase 2a challenge study in Q3 2024.","Expanded into immunology with oral KIT inhibitor program for chronic spontaneous urticaria; development candidate selection targeted for 2024.","G&A expenses rose to $16.5M due to legal fees from patent infringement suit against Pfizer and higher stock compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-012186","json":"https://secwatch.observer/filing/0000950170-24-012186.json","markdown":"https://secwatch.observer/filing/0000950170-24-012186.md","text":"https://secwatch.observer/filing/0000950170-24-012186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/0000950170-24-012186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/enta-20240207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:41:36.738255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}